Compare PMTS & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | CCCC |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.1M | 240.3M |
| IPO Year | 2015 | 2020 |
| Metric | PMTS | CCCC |
|---|---|---|
| Price | $16.30 | $2.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $32.00 | $7.25 |
| AVG Volume (30 Days) | 58.6K | ★ 1.5M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $515,576,000.00 | $30,108,000.00 |
| Revenue This Year | $13.70 | N/A |
| Revenue Next Year | $8.51 | N/A |
| P/E Ratio | $13.51 | ★ N/A |
| Revenue Growth | ★ 12.48 | N/A |
| 52 Week Low | $11.64 | $1.09 |
| 52 Week High | $35.19 | $4.44 |
| Indicator | PMTS | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 33.81 |
| Support Level | $15.83 | $2.50 |
| Resistance Level | $18.23 | $2.69 |
| Average True Range (ATR) | 0.88 | 0.19 |
| MACD | 0.11 | -0.07 |
| Stochastic Oscillator | 54.62 | 2.37 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.